HK1043309A1 - 影響高密度脂蛋白(hdl)胆固醇和載脂蛋白ai、極低密度脂蛋白(vldl)胆固醇和低密度脂蛋白(ldl)胆固醇的水平的組合物和方法 - Google Patents
影響高密度脂蛋白(hdl)胆固醇和載脂蛋白ai、極低密度脂蛋白(vldl)胆固醇和低密度脂蛋白(ldl)胆固醇的水平的組合物和方法Info
- Publication number
- HK1043309A1 HK1043309A1 HK02104818.0A HK02104818A HK1043309A1 HK 1043309 A1 HK1043309 A1 HK 1043309A1 HK 02104818 A HK02104818 A HK 02104818A HK 1043309 A1 HK1043309 A1 HK 1043309A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cholesterol
- density lipoprotein
- low density
- vldl
- apolipoprotein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
PCT/US2000/007870 WO2000057837A2 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1043309A1 true HK1043309A1 (zh) | 2002-09-13 |
Family
ID=23060703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK02104818.0A HK1043309A1 (zh) | 1999-03-26 | 2002-06-28 | 影響高密度脂蛋白(hdl)胆固醇和載脂蛋白ai、極低密度脂蛋白(vldl)胆固醇和低密度脂蛋白(ldl)胆固醇的水平的組合物和方法 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1171078A4 (zh) |
JP (1) | JP2002540127A (zh) |
KR (2) | KR20050044812A (zh) |
AU (1) | AU776684B2 (zh) |
BR (1) | BR0009333A (zh) |
CA (1) | CA2363486C (zh) |
HK (1) | HK1043309A1 (zh) |
IL (2) | IL145526A0 (zh) |
MX (1) | MXPA01009727A (zh) |
NO (2) | NO331779B1 (zh) |
NZ (2) | NZ514350A (zh) |
WO (1) | WO2000057837A2 (zh) |
ZA (1) | ZA200107598B (zh) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
KR101866152B1 (ko) | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
RU2620970C2 (ru) | 2008-12-04 | 2017-05-30 | КьюРНА,Инк., | Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро |
KR101761424B1 (ko) | 2008-12-04 | 2017-07-26 | 큐알엔에이, 인크. | Vegf에 대한 천연 안티센스 전사체의 억제에 의해 맥관 내피 성장 인자(vegf) 관련된 질환의 치료 |
EP2396038B1 (en) | 2009-02-12 | 2015-10-21 | CuRNA, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
ES2656290T3 (es) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2 |
WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
US9155754B2 (en) | 2009-05-06 | 2015-10-13 | Curna, Inc. | Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1 |
US20120046236A1 (en) | 2009-05-06 | 2012-02-23 | Opko Curna Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
WO2010129861A2 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
KR101749356B1 (ko) | 2009-05-18 | 2017-07-06 | 큐알엔에이, 인크. | 재편성 인자에 대한 천연 안티센스 전사체의 억제에 의한 재편성 인자 관련된 질환의 치료 |
EP2432882B1 (en) | 2009-05-22 | 2019-12-25 | CuRNA, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
WO2010138806A2 (en) | 2009-05-28 | 2010-12-02 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
EP2443238B1 (en) | 2009-06-16 | 2017-03-22 | CuRNA, Inc. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
CA2765700C (en) | 2009-06-16 | 2021-01-05 | Opko Curna, Llc | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
JP6073133B2 (ja) | 2009-06-24 | 2017-02-01 | クルナ・インコーポレーテッド | 腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療 |
KR101807324B1 (ko) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 |
WO2011011700A2 (en) | 2009-07-24 | 2011-01-27 | Curna, Inc. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
JP6128848B2 (ja) | 2009-08-05 | 2017-05-17 | クルナ・インコーポレーテッド | インスリン遺伝子(ins)に対する天然アンチセンス転写物の抑制によるインスリン遺伝子(ins)関連疾患の治療 |
WO2011019815A2 (en) | 2009-08-11 | 2011-02-17 | Curna, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
EP2467482A4 (en) | 2009-08-21 | 2013-12-11 | Curna Inc | TREATMENT OF DISEASES RELATED TO "CIP PROTEIN CHIP EXTREME (PROTEIN INTERACTING WITH HSP70)" BY INHIBITION OF CHIP NATURAL ANTISENSE TRANSCRIPT |
WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
ES2664591T3 (es) | 2009-09-25 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG |
US9173895B2 (en) | 2009-12-16 | 2015-11-03 | Curna, Inc. | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 |
CA2782375C (en) | 2009-12-23 | 2023-10-31 | Opko Curna, Llc | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
WO2011090741A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
JP5993744B2 (ja) | 2009-12-29 | 2016-09-14 | カッパーアールエヌエー,インコーポレイテッド | 核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療 |
RU2616283C2 (ru) | 2009-12-31 | 2017-04-13 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 |
US8946181B2 (en) | 2010-01-04 | 2015-02-03 | Curna, Inc. | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 |
US8912157B2 (en) | 2010-01-06 | 2014-12-16 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
RU2611191C2 (ru) | 2010-01-11 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных со связывающим половые гормоны глобулином (гспг), путем ингибирования природного антисмыслового транскрипта к гспг |
JP5981850B2 (ja) | 2010-01-25 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療 |
CN102844435B (zh) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 |
RU2612884C2 (ru) | 2010-04-02 | 2017-03-13 | Курна, Инк. | Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3 |
TWI644675B (zh) | 2010-04-09 | 2018-12-21 | 可娜公司 | 藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病 |
KR101992076B1 (ko) | 2010-05-03 | 2019-06-21 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
EP3299464B1 (en) | 2010-05-26 | 2019-10-02 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
US8980858B2 (en) | 2010-05-26 | 2015-03-17 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA |
CN109112126B (zh) | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
NO2593547T3 (zh) | 2010-07-14 | 2018-04-14 | ||
CA2813901C (en) | 2010-10-06 | 2019-11-12 | Curna, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
US9222088B2 (en) | 2010-10-22 | 2015-12-29 | Curna, Inc. | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
JP6071893B2 (ja) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療 |
US9593330B2 (en) | 2011-06-09 | 2017-03-14 | Curna, Inc. | Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN |
EP2753317B1 (en) | 2011-09-06 | 2020-02-26 | CuRNA, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
WO2013138374A2 (en) | 2012-03-15 | 2013-09-19 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
CN102628060A (zh) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | 一种低脂奶的生产方法 |
US9695462B2 (en) | 2012-11-05 | 2017-07-04 | Shionogi & Co., Ltd. | Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity |
BR112015022009A2 (pt) | 2013-03-14 | 2017-08-29 | Shionogi & Co | Anticorpo monoclonal, inibindo a atividade enzimática de lipase endotelial vascular |
TWI688575B (zh) | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 |
CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
EP4378480A1 (en) * | 2021-07-26 | 2024-06-05 | Purotech Bio, Inc. | Anti-hepatitis b virus agent targeting host factor lipg |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013791A1 (en) * | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
CA2273823C (en) * | 1996-12-06 | 2007-06-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Polypeptides encoded by a human lipase-like gene, compositions and methods |
WO1999032611A1 (en) * | 1997-12-19 | 1999-07-01 | Progenitor, Inc. | A lipase expressed in endothelial cells and methods for its use |
-
2000
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/es active IP Right Grant
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/ko active Search and Examination
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/xx not_active IP Right Cessation
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/ja active Pending
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en active IP Right Grant
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/ko not_active IP Right Cessation
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/pt not_active Application Discontinuation
- 2000-03-24 IL IL14552600A patent/IL145526A0/xx unknown
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/xx unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/no not_active IP Right Cessation
-
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/zh unknown
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20014657D0 (no) | 2001-09-25 |
CA2363486C (en) | 2012-12-18 |
NO20100214L (no) | 2001-11-21 |
AU3918700A (en) | 2000-10-16 |
WO2000057837A2 (en) | 2000-10-05 |
KR20020029651A (ko) | 2002-04-19 |
ZA200107598B (en) | 2003-05-28 |
BR0009333A (pt) | 2002-01-08 |
NZ531180A (en) | 2005-06-24 |
EP1171078A2 (en) | 2002-01-16 |
NO20014657L (no) | 2001-11-21 |
AU776684B2 (en) | 2004-09-16 |
CA2363486A1 (en) | 2000-10-05 |
NZ514350A (en) | 2004-12-24 |
JP2002540127A (ja) | 2002-11-26 |
NO331779B1 (no) | 2012-03-26 |
MXPA01009727A (es) | 2002-07-22 |
KR100887164B1 (ko) | 2009-03-10 |
KR20050044812A (ko) | 2005-05-12 |
WO2000057837A3 (en) | 2001-01-25 |
IL145526A (en) | 2010-11-30 |
IL145526A0 (en) | 2002-06-30 |
WO2000057837A8 (en) | 2001-09-27 |
EP1171078A4 (en) | 2002-11-06 |
WO2000057837A9 (en) | 2001-10-18 |
NO331784B1 (no) | 2012-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL145526A0 (en) | Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol | |
EE200300136A (et) | Kompositsioonid ja meetodid lipoproteiin (a) taseme alandamiseks plasmas ja kardiovaskulaarsete haiguste riskifaktorite vähendamiseks | |
EP1212065A4 (en) | COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL | |
IL140989A0 (en) | Compositions and methods for treating osteoporosis and lowering cholesterol | |
AU2002306930A1 (en) | Plasma processor and method for operating same | |
AU1856997A (en) | Method for raising hdl cholesterol levels | |
IL112593A0 (en) | Methods for inhibiting bone loss and lowering serum cholesterol | |
EP1292603B8 (en) | Methods and compositions for treating hepatitis c virus | |
MY121405A (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines | |
MY130670A (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | |
MY121838A (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
AU3531299A (en) | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | |
AU4446400A (en) | Method and apparatuses for plasma treatment | |
AU5340101A (en) | Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality | |
AU2003204024A1 (en) | Methods for quantitating high-density lipoprotein cholesterol | |
AU6274898A (en) | Bipolar vaporization apparatus and method for arthroscopy | |
AU2002221657A1 (en) | Method and system for preventing the spread of computer viruses | |
DE69931279D1 (de) | Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma | |
AU3065999A (en) | Compositions and methods for treatment of asthma | |
AU2001268601A1 (en) | Methods and apparatus for reducing vibrations induced within fan assemblies | |
AU4558799A (en) | Methods and compositions for generating recombinant adeno-associated virus vectors | |
AU2001243614A1 (en) | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol | |
AU7589498A (en) | Elevation of hdl cholesterol by 4-{(aminothioxomethyl)hydrazono}-4-arylbutyl carbamates | |
IL129220A0 (en) | A pharmaceutical composition for lowering plasma levels of lipoprotein (a) | |
EP1089732A4 (en) | COMPOSITIONS AND METHODS FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS |